Fluid and Biopsy Based Biomarkers in Parkinson's Disease.
Fluid and Biopsy Based Biomarkers in Parkinson's Disease.
复制标题
DOI：
10.1007/s13311-023-01379-z
复制
发表时间：
2023-07
影响因子：
5.7
通讯作者：
Irwin, David J.
中科院分区：
文献类型：
--
作者：
Coughlin, David G.;Irwin, David J.
关键词：
在过去的几年中，用于帕金森病（PD）和其他突触核蛋白病的基于液体和组织的生物标志物已经取得了一些进展。虽然对可以从脊髓液和血浆样品测量的α-突触核蛋白（aSyn）和其他蛋白质的种类的工作仍在继续，但是来自外周组织活检的免疫组织化学和免疫荧光以及α-突触核蛋白接种扩增测定法（a-synuclein seeding amplification assay（aSyn-SAA：包括实时震动诱导转换（RT-QuIC）和蛋白质错误折叠循环扩增（PMCA））现在提供了一个关键的进步，他们的能力，以分类的方式鉴定PD患者中的aSyn种类（即，aSyn + vs aSyn-）;然而，为了增强临床诊断，与病理学负荷具有定量相关性的aSyn特异性测定仍然是未满足的需求。阿尔茨海默病（AD）的共同病理学通常在PD中发现，特别是在那些发展为痴呆和路易体痴呆（DLB）的患者中。tau和淀粉样蛋白β种类的生物流体生物标志物可以检测PD和DLB中的AD共病理，这确实与预后相关，但需要进一步的工作来了解aSyn tau、淀粉样蛋白β和其他病理变化的相互作用，以可转化为临床试验设计和个体化治疗的方式为患者生成全面的生物标志物谱。在线版本包含补充材料，可通过10.1007/s13311-023-01379-z获得。
Several advances in fluid and tissue-based biomarkers for use in Parkinson’s disease (PD) and other synucleinopathies have been made in the last several years. While work continues on species of alpha-synuclein (aSyn) and other proteins which can be measured from spinal fluid and plasma samples, immunohistochemistry and immunofluorescence from peripheral tissue biopsies and alpha-synuclein seeding amplification assays (aSyn-SAA: including real-time quaking induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA)) now offer a crucial advancement in their ability to identify aSyn species in PD patients in a categorical fashion (i.e., of aSyn + vs aSyn −); to augment clinical diagnosis however, aSyn-specific assays that have quantitative relevance to pathological burden remain an unmet need. Alzheimer’s disease (AD) co-pathology is commonly found postmortem in PD, especially in those who develop dementia, and dementia with Lewy bodies (DLB). Biofluid biomarkers for tau and amyloid beta species can detect AD co-pathology in PD and DLB, which does have relevance for prognosis, but further work is needed to understand the interplay of aSyn tau, amyloid beta, and other pathological changes to generate comprehensive biomarker profiles for patients in a manner translatable to clinical trial design and individualized therapies. The online version contains supplementary material available at 10.1007/s13311-023-01379-z.
登录
查看更多内容
老年人同类的α-突触核病和神经心理学症状。
DOI：
10.1186/s13195-015-0101-x
发表时间：
2015
期刊：
Alzheimer's research & therapy
影响因子：
--
作者：
Zaccai J;Brayne C;Matthews FE;Ince PG;MRC Cognitive Function and Ageing Neuropathology Study
通讯作者：
MRC Cognitive Function and Ageing Neuropathology Study
DOI：
10.1084/jem.20200861
发表时间：
2020-11-02
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Barthélemy NR;Horie K;Sato C;Bateman RJ
通讯作者：
Bateman RJ
影响因子：
12.7
作者：
Ashton NJ;Pascoal TA;Karikari TK;Benedet AL;Lantero-Rodriguez J;Brinkmalm G;Snellman A;Schöll M;Troakes C;Hye A;Gauthier S;Vanmechelen E;Zetterberg H;Rosa-Neto P;Blennow K
通讯作者：
Blennow K
影响因子：
11
作者：
Alves, Guido;Bronnick, Kolbjorn;Mulugeta, Ezra
通讯作者：
Mulugeta, Ezra
影响因子：
7.1
作者：
Bargar C;Wang W;Gunzler SA;LeFevre A;Wang Z;Lerner AJ;Singh N;Tatsuoka C;Appleby B;Zhu X;Xu R;Haroutunian V;Zou WQ;Ma J;Chen SG
通讯作者：
Chen SG